AB vs STE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: AB is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AB and STE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AB and STE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

AllianceBernstein is a global investment management firm that runs research-intensive active strategies across equities, fixed income, alternatives, and multi-asset portfolios. It serves three client channels: Institutional Services (pensions, endowments, insurers, and central banks), Retail Services (mutual funds and separately managed accounts), and Private Wealth Management for high-net-worth families. Assets under management reached about $905 billion by mid-2026, split fairly evenly across institutional, retail, and private-wealth clients, and the firm earns the bulk of its revenue from asset-based management fees plus performance fees and Bernstein Research services. Equitable Holdings (EQH) is the controlling owner, holding a large majority economic interest through the operating partnership.

Full AB guide

STERIS plc makes the equipment, chemistries and services that keep hospital operating rooms and medical device production sterile. Three segments carry the business. Healthcare, roughly ~70% of revenue, sells sterilizers, washers, surgical tables, endoscopy reprocessing systems and the consumables and service contracts that follow them into hospitals. Applied Sterilization Technologies (AST), close to ~20% of revenue, runs contract sterilization facilities that gamma-irradiate, e-beam or ethylene oxide treat devices for manufacturers before those devices ship. Life Sciences, near ~10%, supplies cleaning chemistries, small sterilizers and validation services to pharmaceutical producers. Legally the parent is an Irish plc, operationally the company runs out of Mentor, Ohio, and the ordinary shares trade on the NYSE inside the S&P 500. Headcount is roughly ~17,900.

Full STE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AB drivers: Assets under management scale; Distribution-driven income.
• STE drivers: Recurring consumables and service, not equipment sales; Outsourced sterilization volume tied to device manufacturing.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: AB's revenue is tightly linked to markets, so a downturn in equities or bonds would shrink the fee base and the distribution alongside it. For STE, ethylene oxide is the exposure that separates STERIS from an ordinary medical equipment name.

Pick AB if you believe its drivers more; STE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AB and STE guides.

AB. AB trades at a modest earnings multiple (roughly 11x trailing) that reflects its status as a mature, market-sensitive asset manager rather than a growth stock. The standout feature is the high distribution yield near 9%, which is a function of the MLP pass-through structure that returns almost all cash to unitholders each quarter. Because the payout floats with adjusted profit, both the yield and the multiple should be read against the risk that markets or flows turn negative.

STE. STERIS runs a March fiscal year, so the trailing twelve months as of August 2026 spans the final three quarters of fiscal 2026 plus the June 2026 quarter that opened fiscal 2027. Fiscal 2027 first quarter revenue rose ~7% to ~$1.5 billion with adjusted EPS of ~$2.59, and full-year guidance of ~7% to ~8% reported growth was reiterated. The gap between the ~29x trailing and ~21x forward multiple reflects both expected earnings growth of ~9% to ~11% and the sizeable adjustments, including amortization and restructuring, that separate GAAP EPS from the adjusted figure guidance is built on.

Headline figures (approximate, JULY 2026): AB shows assets under management ~$905B, revenue (ttm, gaap) ~$4.5B, q1 2026 adjusted epu ~$0.83, quarterly distribution ~$0.83/unit; STE shows revenue (ttm) ~$6.04 billion, market cap ~$23.2 billion at a share price near ~$239, trailing p/e ~29x on trailing EPS of ~$8.18, forward p/e ~21x on fiscal 2027 adjusted EPS guidance of ~$11.10 to ~$11.30.

AB and STE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AB and STE exposure against your real portfolio. It is not an investment adviser.